Group items tagged

The Medicines and Healthcare products Regulatory Agency (MHRA) has maintained the prescription-only status of Aquiette 2.5mg Tablets for symptoms of overactive bladder, following a public consultation and the review of a reclassification application from the manufacturer Maxwellia Ltd. Aquiette, which contains the active ingredient oxybutynin, is used for the treatment of long-term symptoms of overactive bladder (OAB) in women aged between 18 and 65, such as the urgent need to urinate and frequent urination without pain. The regulator decided against the reclassification of Aquiette 2.5mg Tablets from a prescription-only medicine (POM) to a pharmacy (P) medicine, concluding that a medical prescription continues to be required to ensure the safe use of Aquiette. Since an OAB diagnosis requires medical supervision to ensure that the correct treatment is received, and other health conditions are not overlooked or left untreated, the MHRA said the decision would ensure that the medication is used safely and appropriately under medical supervision. "After taking on board the views of the many patients and healthcare professionals who responded, we have decided to refuse the reclassification of Aquiette 2.5mg Tablets for women with symptoms of overactive bladder (OAB)," Dr Laura Squire, MHRA chief healthcare quality and access officer, said.

The Medicines and Healthcare Products Regulatory Agency (MHRA) is considering the reclassification of Aquiette 2.5mg tablets contains oxybutynin hydrochloride that is used to treat women with milder symptoms of overactive bladder from Prescription-Only-Medicine (POM) to Pharmacy (P) medicine. The agency is encouraging pharmacists, GPs and other health care professionals, the public and women to take part in the reclassification consultation to make a treatment for overactive bladder available for women without the need for a prescription. Public consultation on a set of proposals to make Aquiette 2.5mg Tablets (oxybutynin hydrochloride) available from pharmacies will close on 13 May, 2022. It would be the first time a medicine for the treatment of overactive bladder would be available without prescription, if the reclassification consultation receives positive responses. After the decision is made to reclassify this treatment, pharmacists will have access to training materials and a checklist to enable them to identify women who can be supplied this medicine safely.

The Medicines and Healthcare products Regulatory Agency (MHRA) has cautioned against buying weight-loss medicines without a prescription from beauty salons, unregistered pharmacy websites or social media platforms as such products could pose "serious health risks." Consumers are reminded that the only safe way to obtain genuine weight-loss medication is through a legitimate pharmacy, including licensed online pharmacies, with a prescription from a qualified healthcare professional. To combat the illegal sale of these medicines, the MHRA's Criminal Enforcement Unit is working closely with social media platforms, technology companies, the police and Border Force. Andy Morling, MHRA deputy director of Criminal Enforcement, highlighted the dangers of purchasing these medications from unverified sources: "At this time of year, with many of us thinking about shedding a little excess weight, we see people offering weight loss medicines for sale as a quick fix, without a healthcare professional's prescription, from beauty salons, websites and on social media. "These are not cosmetic treatments; they are powerful medicines that can only be legally and safely dispensed against a prescription issued by a healthcare professional."

People are advised to be mindful of medications that may cause sun reactions, and to watch out for dodgy hay fever treatments and fake weight loss pens. For those traveling abroad, the MHRA advises considering the suitability of medicines available to reduce the risk of contracting tropical diseases. Dr Alison Cave, Chief Safety Officer at the MHRA, said: "The summer is an exciting time for many of us, as we take time off to travel and enjoy the warmer weather. "But it is important to understand what this time of year means for our medicines and medical devices, and take the precautions necessary to use products safely and protect ourselves." Watch out for dodgy hay fever treatments Millions of Britons suffer from hay fever symptoms in the summer. The MHRA advises consulting a healthcare professional to find the best treatment for your symptoms. People are also warned to be cautious of medicines advertised as hay fever treatments but not approved for use in the UK, such as Kenalog. This is a prescription-only steroid injection licensed as a medicine for other conditions, but not for the treatment of hay fever.

This Pharmacy First Common Ailments service will help patients seek treatment for seven common conditions directly from a pharmacy without the need for a GP appointment or prescription. Launching on 31 January next year although it is subject to IT being ready, the service will cover ailments including "sinusitis, sore throat, earache, infected insect bites, impetigo, shingles, and uncomplicated urinary tract infections (UTIs)" in women. People with symptoms of the above seven conditions will be supplied with a prescription-only treatment under a Patient Group Direction (PGD). Patients seeking assistance at the pharmacy, whether walk-in or referred by NHS 111, GPs, or other sources, can receive consultations. The new service includes self-referring patients plus referrals, and the Community Pharmacist Consultation Service (CPCS) will also be a part of it.

The Medicines and Healthcare products Regulatory Agency (MHRA) has reclassified codeine linctus, a medicine used for the treatment of dry cough, from a pharmacy-only medicine (P) to a prescription-only medicine (POM) owing to the risk of dependence, addiction, and overdose. This implies that the dry cough syrup, which is also known as codeine oral solution, can only be dispensed upon the submission of a prescription at a pharmacy, rather than being accessible over the counter upon request. Patients are cautioned that as an opioid medicine, codeine can be addictive, and the risk of addiction may increase, particularly with prolonged use over an extended period. According to the medicines regulator, codeine is converted into morphine by the liver enzyme CYP2D6. In individuals identified as ultra-rapid metabolizers, this conversion from codeine to morphine occurs at a faster rate than in others. "If you want to stop taking it and have been taking codeine linctus for a long time, then it is important to reduce the amount you take slowly with the help of your prescriber," the agency said in its drug safety update issued on Tuesday, 20 February.

Maxwellia has revealed its plans to switch some of its medicines in the self-care category from prescription-only-medicine (POM) to a pharmacy (P) medicine. After authorising the switch of Maxwellia's two brands of desogestrel contraceptive pills, Lovima and Hana, MHRA has opened a public consultation on reclassification of Aquiette (overactive bladder treatment) 2.5mg tablets manufactured by the company to be made available from pharmacies. "Maxwellia is currently looking at a number of medicines which treat a range of conditions in major public health categories that can be 'switched' from needing a prescription to being conveniently bought at a local high street or supermarket pharmacy. With its foot firmly on the accelerator it has other applications under assessment with the MHRA, including women's health products," the company stated in a recent statement. "Push to convert more prescription medicines to pharmacy medicines will firmly position pharmacists at heart of nation's public health, helping futureproof NHS," the medicine said.

NHS West Yorkshire Integrated Care Board (ICB)'s decision to withdraw gluten free prescriptions for people with coeliac disease across Leeds and Calderdale has disappointed Coeliac UK. In a statement released on Thursday, the charity, which provides support and advice to those living with the disease, has raised "grave concerns" about the decision, warning that it will have a detrimental impact on the coeliac community. The policy is currently implemented across the ICB's other places including Bradford district and Craven, Kirklees and Wakefield district, preventing coeliac patients from accessing gluten free bread and flour mix on prescription. NHS West Yorkshire ICB wants to align its gluten free prescribing guidelines across its five places. But the charity is worried that the additional cost of gluten free staple products will poses a real challenge to maintaining the gluten-free diet, which is the only treatment for the condition.

Coeliac UK has raised grave concerns about the decision by NHS Leicester, Leicestershire and Rutland Integrated Care Board (ICB) to withdraw gluten free prescriptions for people with a diagnosis of coeliac disease and its potential impact on their health. The charity highlighted the significant additional cost of gluten free staple substitute products, which poses a real challenge to maintaining the gluten free diet, the only treatment for the condition. Coeliac UK noted that 72 per cent of respondents to a recent public consultation disagreed with the ICB's proposal to stop gluten free prescribing, and said it is "deeply concerned" by the potential impact of the decision to proceed with removal of provision. The charity accused the ICB of making no meaningful effort to reduce the impact of this policy change for those on low incomes, despite the additional cost of gluten free food being highlighted by 58 per cent of those who disagreed with the proposal.

The UK government has announced plans to update legislation to enable more services and individuals to provide take-home supplies of naloxone - a life-saving opioid overdose antidote - over the next few weeks. Naloxone can immediately reverse the effects of an opioid overdose by reversing breathing difficulties. The medicine can be administered by anyone in an emergency. However, current legislation allows only drug and alcohol treatment services to supply it without a prescription to individuals for future use. The Department of Health and Social Care (DHSC) confirmed on Tuesday (14 May) that more professionals, including nurses, paramedics, police officers, probation officers and pharmacy professionals, will be able to supply the medicine without a prescription to save lives. Health and Social Care Secretary Victoria Atkins warned that opioid addiction can ruin lives and it accounts for the largest proportion of drug-related deaths across the UK.

The Community Pharmacy Walk-In Consultation Service (WICS), offering treatment for various minor ailments, recorded 19,567 consultations in 2024. This marks a 61 per cent increase compared to the 12,138 consultations recorded in 2023, according to data released by Community Pharmacy Cornwall (CPC) and obtained by The Pharmaceutical Journal. Launched in community pharmacies across Cornwall and the Isles of Scilly in January 2021, the minor ailment scheme is commissioned by the NHS and CPC. It enables locally accredited community pharmacists to supply prescription-only-medicines (POMs) for the treatment of several common conditions utilising patient group directions (PGDs) that Pharmacy First does not currently cover. These include vaginal candidiasis (vaginal thrush), dermatitis, migraine, conjunctivitis, and emergency hormonal contraception. Since its launch, the service has facilitated over 38,000 consultations, with 80 per cent of them resulting in advice or treatment that concluded the consultation in the pharmacy. WICS data also indicates that the service has helped avoid an estimated 30,000 GP appointments and more than 500 inappropriate A&E visits since its inception.

The Medicines and Healthcare products Regulatory Agency (MHRA) and the Committees of Advertising Practice (CAP) have issued a joint enforcement notice about the 'illegal' advertising of Kenalog injections on digital platforms. The notice warns all organisations offering Kenalog as a 'hay fever treatment' to stop advertising it in any of their social media or website advertising. "Kenalog is a prescription-only medicine (POM), which must not be directly or indirectly advertised to the public. Kenalog is not licensed for the treatment of hay fever in the UK, although it is offered by some beauty and aesthetics clinics, under the personal responsibility of an individual prescriber, and advertised widely on social media," said MHRA. "Now, advertisers must ensure that all references to Kenalog in the text, images or emojis on social media are removed, as well as commonly-used descriptive phrases for the jab such as 'hay fever injection' or hay fever jab' or any account names, testimonials or memes by 29 August 2022." After this date, the CAP's compliance team will remove non-compliant ads using targeted software and those who continue to promote it may be referred to the MHRA for further enforcement action.

The much-awaited Pharmacy First service has been launched in England, enabling patients to get treatment for seven common conditions from their community pharmacists without needing to see a GP. According to NHS England, a total of 10,265 community pharmacies, which is equivalent to more than nine in ten community pharmacies in the country, will be offering the ground-breaking initiative. The new scheme allows highly trained pharmacists to give advice and prescription-only medicines for minor ailments including sinusitis, sore throat, earache, infected insect bite, impetigo, shingles, and uncomplicated urinary tract infections in women (under the age of 65). With this major expansion of pharmacy services, the NHS is aiming to free up 10 million GP appointments a year while giving the public more choice in where and how they access care.

The Company Chemists' Association (CCA) has urged NHS England to expand the Pharmacy First service by increasing treatment options, adding more conditions, and integrating Independent Prescribing into the service. This would further promote pharmacists as antimicrobial stewards while enhancing patient access to urgent care, it said. Managing patient demand for antibiotics remains a challenge for healthcare professionals, including pharmacists. However, a new report by CCA confirms that pharmacists are acting as responsible providers of antibiotics, in line with Antimicrobial Resistance (AMR) guidelines. The service allows pharmacies to provide advice and treatment, including prescription-only medication, for seven common conditions: earache, uncomplicated urinary tract infections (UTIs) in women, sore throat, sinusitis, infected insect bites, impetigo, and shingles. Patients can access the service via GP referrals or by visiting or contacting a pharmacy directly.

We are specialized in supplying of anti-anxiety medications and Pain medications like XANAX, OXYCODONE, HYDROCODONE, DIAZEPAM (VALIUM) and many others which are used for the treatment and management of anxiety, pain and alcohol withdrawal symptoms. our main objective is to satisfy our customers and we only supply FDA approved medications and you do not need a prescription to buy from us. Buy Vicodin Online http://buy-ativanonline.com/ https://buy-ativanonline.com/shop/ http://buy-ativanonline.com/product/buy-oxycontin-online/ http://buy-ativanonline.com/product/buy-dilaudid-online/ http://buy-ativanonline.com/product/buy-adderall-online/ http://buy-ativanonline.com/product/buy-vicodin-online/ http://buy-ativanonline.com/product/buy-ritalin-online/ http://buy-ativanonline.com/product/buy-suboxone-online/ http://buy-ativanonline.com/product/buy-ambien-online/ http://buy-ativanonline.com/product/buy-dexedrine-online/ http://buy-ativanonline.com/product/buy-demerol-online/ Contact Us Phone : +1 (740) 240-2244 Email : contact@buy-ativanonline.com

We are specialized in supplying of anti-anxiety medications and Pain medications like XANAX, OXYCODONE, HYDROCODONE, DIAZEPAM (VALIUM) and many others which are used for the treatment and management of anxiety, pain and alcohol withdrawal symptoms. our main objective is to satisfy our customers and we only supply FDA approved medications and you do not need a prescription to buy from us. Buy Ritalin Online http://buy-ativanonline.com/ https://buy-ativanonline.com/shop/ http://buy-ativanonline.com/product/buy-oxycontin-online/ http://buy-ativanonline.com/product/buy-dilaudid-online/ http://buy-ativanonline.com/product/buy-adderall-online/ http://buy-ativanonline.com/product/buy-vicodin-online/ http://buy-ativanonline.com/product/buy-ritalin-online/ http://buy-ativanonline.com/product/buy-suboxone-online/ http://buy-ativanonline.com/product/buy-ambien-online/ http://buy-ativanonline.com/product/buy-dexedrine-online/ http://buy-ativanonline.com/product/buy-demerol-online/ Contact Us Phone : +1 (740) 240-2244 Email : contact@buy-ativanonline.com

We are specialized in supplying of anti-anxiety medications and Pain medications like XANAX, OXYCODONE, HYDROCODONE, DIAZEPAM (VALIUM) and many others which are used for the treatment and management of anxiety, pain and alcohol withdrawal symptoms. our main objective is to satisfy our customers and we only supply FDA approved medications and you do not need a prescription to buy from us. Buy Suboxone Online http://buy-ativanonline.com/ https://buy-ativanonline.com/shop/ http://buy-ativanonline.com/product/buy-oxycontin-online/ http://buy-ativanonline.com/product/buy-dilaudid-online/ http://buy-ativanonline.com/product/buy-adderall-online/ http://buy-ativanonline.com/product/buy-vicodin-online/ http://buy-ativanonline.com/product/buy-ritalin-online/ http://buy-ativanonline.com/product/buy-suboxone-online/ http://buy-ativanonline.com/product/buy-ambien-online/ http://buy-ativanonline.com/product/buy-dexedrine-online/ http://buy-ativanonline.com/product/buy-demerol-online/ Contact Us Phone : +1 (740) 240-2244 Email : contact@buy-ativanonline.com

Proprietary Association of Great Britain, PAGB - which represents manufacturers of branded over-the-counter (OTC) medicines, self-care medical devices and food supplements - on Tuesday (12 December) celebrated 40 years of reclassification of medicines. Expanding self-care for common ailments and minor injuries will not only help ease pressure on primary care services, but also provides significant potential savings for the NHS, the consumer healthcare association highlighted during the event. Nurofen (ibuprofen) and Imodium (loperamide) were the first medicines to go through Medicines and Healthcare products Regulatory Agency (MHRA)'s switch process in 1983 to make them available over the counter - OTC. Other reclassified medicines which were once available on prescription only include Voltarol (diclofenac dimethylammonium), Canesten (clotrimazole), Nexium (esomeprazole), Nicorette, Nicotinell and Niquitin (nicotine replacement therapies), Regaine (minoxidil), Viagra Connect (sildenafil), Cialis Together (tadalafil) for erectile dysfunction and Gina (estradiol hemihydrate) for the treatment of postmenopausal symptoms such as vaginal dryness.

Maxwellia has appointed Ian Adamson as strategic advisor to shape the next phase of pharmacy medicine launches - a process which involves identifying and converting suitable prescription only medicines into versions people can choose to buy under the supervision of a pharmacist. Ian brings over 30 years' international consumer health and personal care experience to the Maxwellia team. He is currently an advisor to the board of the UK independent pharmacy chain Day Lewis plc, an advisor to the board of Spanish healthcare company ReVa Europe S.L and board advisor to East Midlands Pharmaceuticals Ltd. Prior to this Ian was Chief Commercial Officer and a main board director at SSL International plc (prior to its sale to Reckitt Benckiser) with responsibility for a $1bn portfolio of brands, which included Durex and Scholl. Ian's appointment follows the landmark reclassification of the progestogen only pill by the MHRA, a change spearheaded by Maxwellia, and the company's subsequent launch of its first product Lovima in July 2021; and the current MHRA public consultation on the reclassification of Maxwellia's new pharmacy brand, Aquiette 2.5mg Tablets (Oxybutynin Hydrochloride) for the treatment of overactive bladder symptoms which are not adequately controlled by bladder training alone.

No one can deny the fact that any sort of addiction is injurious to health despite knowing it many people get involved in the usage of drugs. One of an alarming fact is that people are not only restricted to illegal drugs addiction but people are getting addicted to prescription drugs also...